Key facts
- Neupulse’s last known valuation is $19.7M (Feb 2026).
- It has raised $10.1M; the latest was Later Stage VC ($4.0M) in Feb 2026.
- Notable investors include Mercia Ventures, Maven Capital Partners UK, Midlands Engine Investment Fund, Campbell Johnston Clark, Eos Advisory — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Neupulse
- ·The full record, as it builds
Funding rounds
No funding rounds for Neupulse are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neupulse
Developer of a neuromodulation device designed to help individuals monitor and get control of their tics. The company offers a wearable wristwatch-like device to monitor rhythmic peripheral nerve stimulation with the help of non-drug treatment, enabling users to detect Tourette Syndrome (TS) and associated co-occurring brain health conditions.
- Sector
- Healthcare
- HQ
- Nottingham, United Kingdom
- Founded
- 2021
- Employees
- 13
- Website
- neupulse.co/
- Ownership
- Privately Held (backing)
Neupulse doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neupulse shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neupulse in its N-PORT filings yet. We sweep new filings monthly.